Please login to the form below
antimicrobial
This page shows the latest antimicrobial news and features for those working in and with pharma, biotech and healthcare.
Pfizer acquires Amplyx Pharmaceuticals, including new potential class of therapeutics
issue of antimicrobial resistance.
Latest news
-
Roche buys GenMark for $1.8bn to bolster diagnostics portfolio
The rapid identification of bloodstream infections and the detection of antimicrobial resistance genes are more essential than ever for hospitals and their patients,” he added.
-
AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance
issue of antimicrobial resistance.
-
Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m
is a part of the broader issue of antimicrobial resistance.
-
New Oxford research institute established to tackle antimicrobial resistance
Institute has received £100m in funding from Ineos. A new research institute at the University of Oxford has been established to fight against antimicrobial resistance (AMR). . ... Last year, The International Federation of Pharmaceutical Manufacturers
-
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
In the UK, over 5, 000 deaths per year are attributed to antimicrobial resistance (AMR), with over 25, 000 deaths per year attributed to AMR in the EU. ... AMR is a major health burden wherein bacteria, fungi, viruses and parasites become resistant to a
Roche buys GenMark for $1.8bn to bolster diagnostics portfolio
AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance
Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m
New Oxford research institute established to tackle antimicrobial resistance
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
More from news
Approximately 48 fully matching, plus 74 partially matching documents found.
Latest Intelligence
-
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
However, we cannot be complacent when it comes to another rising infectious threat: antimicrobial resistance, or AMR.
-
Rebranding in an evolving world
in recent years, despite the ever- increasing health burden of antimicrobial resistance globally.
-
Rethinking our approach to infectious disease preparedness
Antimicrobial resistance. There is a second pandemic that we have to deal with – the rising tide of antimicrobial resistance, where bacteria are becoming resistant to the antibiotics we routinely use to
-
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19. ... The World Health Organization (WHO) states that antimicrobial resistance (AMR) is a global concern.
-
The global antibiotic crisis: a 2020 perspective
In the forward of the 2019 CDC report on the threat posed by antimicrobial resistance he said simply: ‘We need stop referring to a coming post-antibiotic era – it’s already ... The plan is the latest step towards the government’s broader 20-year
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
Rebranding in an evolving world
Rethinking our approach to infectious disease preparedness
How COVID-19 is accelerating the threat of antimicrobial resistance
The global antibiotic crisis: a 2020 perspective
More from intelligence
Approximately 8 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
resistance, which is a part of the broader issue of antimicrobial resistance.
-
IFPMA names new communications director
and to enable government to meet ambitious goals such as universal health coverage, global health security and continued innovation in areas of high unmet health needs such as antimicrobial resistance.
-
Destiny Pharma appoints new CEO
Destiny Pharma has appointed Neil Clark as CEO as the Brighton, UK-based firm plans a phase IIb trial for its lead antimicrobial candidate.
-
New health ministers and re-appointments after reshuffle
Ellison, who reprises her role as the secretary for public health that she has held since 2013, also has a wide remit that includes pharma as will have responsibility for: antimicrobial
-
Xellia forms scientific advisory board
drugs to help tackle the global crisis of antimicrobial resistance.”. ... Antimicrobial resistance is a huge area of unmet medical need and one of the greatest threats to human health.
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
IFPMA names new communications director
Destiny Pharma appoints new CEO
New health ministers and re-appointments after reshuffle
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
For years, concerns have been mounting about a problem that has the potential to set our health services back 100 years: the rise of antimicrobial resistance. ... WHO. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Published
-
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Other recent progress includes NovaBiotics’ novel antimicrobial-immunomodulator, Nylexa, which is now set to enter phase 3 clinical trials in the UK for COVID-19 and non-COVID pneumonia (in hospitalised ... NP432, derived from NovaBiotics’
-
Antibiotic resistance: The silent pandemic
Up to 2 billion people, mainly in low- and middle-income countries, lack access to antimicrobials. ... Available at: https://www.healtheuropa.eu/antimicrobial-resistance/88272/. Accessed November 2019. World Health Organization. WHO global strategy for
-
Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. ... Her illness is due to antimicrobial resistance (AMR) and it is not as rare as you might think.
-
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians navigating ... Antimicrobial resistance claims 5,
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital strategist
-
Competitive
-
Digital project manager
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Recruiting patients for real-world studies – the power of a digital campaign
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
